Get the Stockscreener App
106.47
0.60%
0.63
After Hours:
106.47
Boston Scientific Corp stock is traded at $106.47, with a volume of 6.35M.
It is up +0.60% in the last 24 hours and down -0.06% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$105.84
Open:
$106.68
24h Volume:
6.35M
Relative Volume:
0.88
Market Cap:
$157.52B
Revenue:
$18.49B
Net Income/Loss:
$2.51B
P/E Ratio:
63.38
EPS:
1.68
Net Cash Flow:
$2.72B
1W Performance:
+3.21%
1M Performance:
-0.06%
6M Performance:
+3.66%
1Y Performance:
+40.85%
1-Day Range:
$106.10
$107.25
1-Week Range:
$104.69
$108.53
52-Week Range:
$71.88
$108.53
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
106.47 | 156.58B | 18.49B | 2.51B | 2.72B | 1.68 |
|
ABT
Abbott Laboratories
|
128.01 | 219.83B | 43.11B | 13.98B | 6.66B | 7.98 |
|
SYK
Stryker Corp
|
400.57 | 153.13B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.44 | 117.84B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.47 | 46.04B | 5.69B | 4.15B | 623.10M | 6.95 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific Corporation Reversal Rally May Surprise BearsOversold Bounce Stock Play Ideas Gain Attention - metal.it
Europe Defibrillator Market Forecast and Company Analysis Report 2025-2033 Featuring Medtronic, Philips, Nihon Kohden, Boston Scientific, Stryker, Asahi Kasei, LivaNova, and Abbott - GlobeNewswire Inc.
Boston Scientific’s SWOT analysis: innovation drives stock amid challenges - Investing.com
What are the technical indicators suggesting about Boston Scientific CorporationSuperior returns - jammulinksnews.com
RBC Capital Raises PT on Boston Scientific Corporation (BSX) to $125 From $120 - Insider Monkey
What are the latest earnings results for Boston Scientific CorporationIdentify undervalued stocks poised to rally - jammulinksnews.com
How does Boston Scientific Corporation compare to its industry peersMaximize portfolio growth with professional advice - jammulinksnews.com
Boston Scientific Corporation (BSX) Is One Of The Most Reliable Companies, Says Jim Cramer - Insider Monkey
TD Cowen Reiterates a Buy Rating on Boston Scientific Corporation (BSX) - Insider Monkey
10 Best Strong Buy Healthcare Stocks to Buy Now - Insider Monkey
FSHPU seeks shareholder OK to cut extension fee to $60k/month, preserve GFT merger | BSX SEC FilingForm 144 - Stock Titan
Boston Scientific's (NYSE:BSX) investors will be pleased with their solid 173% return over the last five years - Yahoo.co
Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance - MSN
Boston Scientific Reports Strong Q2 2025 Results - The Globe and Mail
Boston Scientific (BSX) Target Price Raised by Raymond James | B - GuruFocus
Boston Scientific (BSX) Price Target Raised by Oppenheimer | BSX Stock News - GuruFocus
Boston Scientific stock price target raised to $125 from $120 at RBC Capital - Investing.com
Is Boston Scientific Corporation stock overhyped or has real potentialSuperior stock growth - jammulinksnews.com
Boston Sci posts 117% U.S. PFA growth, halves tariff impact - BioWorld MedTech
Boston Scientific stock price target raised to $130 from $124 at Bernstein - Investing.com Canada
Boston Scientific (BSX) Price Target Increased by RBC Capital | - GuruFocus
BSX: Boston Scientific Sees Price Target Raised by Truist Securi - GuruFocus
Stocks making big moves yesterday: Power Integrations, Booz Allen Hamilton, Wendy's, SentinelOne, and Boston Scientific - Yahoo Finance
Boston Scientific (BSX) Price Target Raised by Baird Analyst | B - GuruFocus
Boston Scientific Corporation (NYSE:BSX) Q2 2025 Earnings Call Transcript - Insider Monkey
Boston Scientific stock price target raised to $140 from $130 at Mizuho - Investing.com
Boston Scientific (BSX) Price Target Increased by Baird | BSX Stock News - GuruFocus
Boston Scientific (BSX) Price Target Raised to $118 by Oppenheimer | BSX Stock News - GuruFocus
UBS Boosts Price Target for Boston Scientific (BSX) Amid Strong Performance | BSX Stock News - GuruFocus
Boston Scientific stock price target raised to $135 by UBS on strong product cycle - Investing.com
Company News for Jul 24, 2025 - The Globe and Mail
Boston Scientific stock price target raised to $124 by Wells Fargo on PFA growth - Investing.com
Boston Scientific (BSX) Sees Price Target Boost from Barclays | - GuruFocus
Boston Scientific Corp (BSX) Q2 2025 Earnings Call Highlights: Surpassing Expectations with ... By GuruFocus - Investing.com Canada
Boston Scientific: Q2 Earnings Snapshot - Greenwich Time
Boston Scientific’s Strong Financial Performance and Positive Outlook Earns Buy Rating - TipRanks
Should You Buy or Sell Boston Scientific Stock Ahead of Its Upcoming Earnings? - Nasdaq
Why Boston Scientific (BSX) Stock Is Up Today - Yahoo Finance
Boston Scientific lifts 2025 outlook following 29% Q2 cardiovascular profit rise - Yahoo Finance
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up - The Globe and Mail
Boston Scientific stock price target raised to $120 by BofA Securities - Investing.com
Boston Scientific (BSX) Price Target Increased by BofA Analyst | - GuruFocus
Boston Scientific Presses Its Advantage in Pulsed Field Ablation - Morningstar
Boston Scientific halves expected tariff hit - MedTech Dive
Boston Scientific Lifts Outlook On Cardiovascular Revenue Growth - Finimize
Boston Scientific lifts annual profit forecast, sees smaller tariff impact - Reuters
Boston Scientific lifts annual profit forecast, sees smaller tariff impact By Reuters - Investing.com
Boston Scientific stock hits all-time high at 107.76 USD By Investing.com - Investing.com Nigeria
Boston Scientific stock hits all-time high at 107.76 USD - Investing.com
Earnings call transcript: Boston Scientific Q2 2025 beats expectations, stock rises - Investing.com
Boston Scientific lifts annual profit view on steady heart devices demand - Yahoo.co
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):